Drug
Orvepitant clinical trials
Also written GW823296.
Includes 2 studies of Orvepitant maleate.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
10 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 3 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
GlaxoSmithKline (6) · Nerre Therapeutics Ltd. (4)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses orvepitant is read from its arms, and is right about nine times in ten.
Testing it · 10
- Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary FibrosisCompletedPhase 2Nerre Therapeutics Ltd.NCT05185089Written as Orvepitant Maleate
- A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory CoughCompletedPhase 2Nerre Therapeutics Ltd.NCT02993822Written as Orvepitant Maleate
- Mass Balance Study of [14C]-Orvepitant Oral Solution in Healthy Male SubjectsCompletedPhase 1Nerre Therapeutics Ltd.NCT04387981Written as [14C]-orvepitant
- A Study of the Efficacy and Safety of Orvepitant in Subjects With Pruritus Associated With Atopic DermatitisWithdrawnPhase 2Nerre Therapeutics Ltd.NCT03464526Written as Orvepitant
- A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive DisorderTerminatedPhase 2GlaxoSmithKlineNCT00880048Written as orvepitant
- A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive DisorderTerminatedPhase 2GlaxoSmithKlineNCT00880399Written as orvepitant
- Orvepitant (GW823296) in Adult Post Traumatic Stress DisorderCompletedPhase 2GlaxoSmithKlineNCT01000493Written as orvepitant
- 28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296)CompletedPhase 1GlaxoSmithKlineNCT00511654Written as GW823296 tablet
- Food and Relative Bioavailability StudyCompletedPhase 1GlaxoSmithKlineNCT00843011Written as Orvepitant
- GW823296 Repeat Dose Study In Healthy Male And Female SubjectsCompletedPhase 1GlaxoSmithKlineNCT00675116Written as GW823296
Given in every arm · 1 — orvepitant is usual care beside what is tested
Codes
What other systems call orvepitant · ClinicalTrials.gg INT006378
- MeSH (NLM) C584555orvepitantOne source NLM
- UNII (FDA) IIU6V0W3JDORVEPITANTConfirmed FDA, NLM, Wikidata
- Wikidata Q27280750orvepitantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C90613OrvepitantOne source FDA
- DrugBank DB12427One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C584555 | orvepitant | One source NLM |
| UNII (FDA) | IIU6V0W3JD | ORVEPITANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27280750 | orvepitant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C90613 | Orvepitant | One source FDA |
| DrugBank | DB12427 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.